Capital World Investors
NVCR icon

Capital World Investors’s NovoCure NVCR Stock Holding History

Capital World Investors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,000,000
Closed -$25.8M – 594
2025
Q3 		$25.8M Sell
2,000,000
-4,382,848
-69% -$58.6M ﹤0.01% 469
2025
Q2 		$114M Buy
6,382,848
+1,167,319
+22% +$20.3M 0.02% 336
2025
Q1 		$92.9M Buy
5,215,529
+400,000
+8% +$9.08M 0.02% 345
2024
Q4 		$144M Buy
4,815,529
+507,311
+12% +$10.7M 0.02% 306
2024
Q3 		$67.3M Buy
4,308,218
+2,000,003
+87% +$36.3M 0.01% 374
2024
Q2 		$39.5M Hold
2,308,215
– – 0.01% 401
2024
Q1 		$36.1M Sell
2,308,215
-968,781
-30% -$14.2M 0.01% 420
2023
Q4 		$48.9M Sell
3,276,996
-5,601,735
-63% -$75M 0.01% 384
2023
Q3 		$143M Sell
8,878,731
-2,511,814
-22% -$72.4M 0.03% 296
2023
Q2 		$473M Sell
11,390,545
-2,634,512
-19% -$164M 0.09% 199
2023
Q1 		$843M Buy
14,025,057
+1,175,538
+9% +$93.9M 0.17% 138
2022
Q4 		$943M Buy
12,849,519
+61,280
+0.5% +$4.61M 0.2% 122
2022
Q3 		$972M Buy
12,788,239
+1,065,755
+9% +$83.1M 0.22% 112
2022
Q2 		$815M Sell
11,722,484
-928,159
-7% -$69.9M 0.17% 135
2022
Q1 		$1.05B Buy
12,650,643
+26,600
+0.2% +$1.96M 0.18% 129
2021
Q4 		$948M Buy
12,624,043
+3,543
+0% +$356K 0.15% 147
2021
Q3 		$1.47B Buy
12,620,500
+774,799
+7% +$117M 0.25% 92
2021
Q2 		$2.63B Buy
11,845,701
+3,208,178
+37% +$624M 0.45% 54
2021
Q1 		$1.14B Buy
8,637,523
+892,485
+12% +$141M 0.21% 119
2020
Q4 		$1.34B Buy
7,745,038
+1,115,021
+17% +$153M 0.26% 96
2020
Q3 		$738M Buy
6,630,017
+1,326,769
+25% +$106M 0.16% 134
2020
Q2 		$314M Buy
5,303,248
+367,900
+7% +$24.2M 0.08% 210
2020
Q1 		$332M Sell
4,935,348
-99,972
-2% -$7.9M 0.1% 179
2019
Q4 		$424M Buy
5,035,320
+491
+0% +$39.6K 0.09% 193
2019
Q3 		$377M Sell
5,034,829
-199,983
-4% -$16M 0.09% 192
2019
Q2 		$331M Buy
5,234,812
+200,415
+4% +$10.2M 0.08% 202
2019
Q1 		$243M Buy
5,034,397
+2,240,586
+80% +$108M 0.06% 225
2018
Q4 		$93.5M Buy
2,793,811
+528,500
+23% +$19.3M 0.03% 291
2018
Q3 		$119M Buy
2,265,311
+386,600
+21% +$15.4M 0.03% 292
2018
Q2 		$58.8M Buy
+1,878,711
New +$52.3M 0.01% 354

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capital World Investors's NVCR Position: Q4 2025 in Review

Capital World Investors sold out of NovoCure (NVCR) in Q4 2025, closing a stake of 2,000,000 shares — an estimated $25.8M sold.

Capital World Investors first reported a position in NVCR in Q2 2018 and held it in 30 quarters. The position peaked at $2.63B in Q2 2021. 239 funds tracked by Wall St. Rank hold NVCR as of Q4 2025.

  • Capital World Investors reported no remaining NovoCure position as of Q4 2025 after selling out during the quarter.
  • Capital World Investors sold 2,000,000 NovoCure shares in Q4 2025, an estimated $25.8M.
  • Capital World Investors first reported a position in NovoCure in Q2 2018 and held it in 30 quarters.
  • Capital World Investors's NovoCure position peaked at $2.63B in Q2 2021.
  • 239 funds tracked by Wall St. Rank held NovoCure as of Q4 2025.

Based on Capital World Investors's 13F filing for Q4 2025, filed 11 Feb 2026.